Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Search
Drug Profile

Berdazimer sodium - SB 204 - Ligand Pharmaceuticals

Alternative Names: MAP3-NONOate - SB-204; NVN1000-SB204; SB-204

Latest Information Update: 25 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Novan Inc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Esters; Free radicals; Macromolecular substances; Nitrogen oxides; Nitroso compounds; Non-opioid analgesics; Propylamines; Silicates; Silicon compounds; Skin disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Discontinued Staphylococcal infections

Most Recent Events

  • 27 Sep 2023 Ligand Pharmaceuticals acquires all the rights of all the assets related to the NITRICIL technology platform from Novan
  • 09 Sep 2021 Novan announces intention to submit NDA to US FDA for Acne vulgaris in 2024
  • 09 Sep 2021 Phase III development for Acne vulgaris (In adolescents, In adults, In children, In the elderly) is still ongoing in USA (Topical,Gel) (Novan's pipeline, September 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now